<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518828</url>
  </required_header>
  <id_info>
    <org_study_id>HiLo-HF- 2 Pilot Trial</org_study_id>
    <nct_id>NCT02518828</nct_id>
  </id_info>
  <brief_title>High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure</brief_title>
  <acronym>HiLo</acronym>
  <official_title>High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Innovates Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot trial is to determine whether inpatients presenting to
      the Emergency Department (ED) with symptoms suggestive of Acute Heart Failure (AHF), who
      receive supplemental oxygen adjusted at either a high (SpO2 range ≥96%) or low (SpO2 range
      90-92%) oxygen saturation level, leads to greater reduction in N-terminal-proBNP (NT-proBNP)
      at 72 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to either a high (SpO2 range ≥96%) or low (SpO2 range 90-92%)
      oxygen after informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NT-proBNP from baseline to 72 hours</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnea using the visual analog scale (VAS) from baseline to 72 hours</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global symptoms using the Patient Global Assessment scale (PGA) from baseline to 72 hours</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Expiratory Flow Rate (PEFR) from baseline to 72 hours</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of worsening heart failure (WHF) events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day clinical events</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality, HF readmission, days alive and out of hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average z-score from the combination of these outcomes: PGA, NT-proBNP, 7-day WHF, 30-day mortality and re-hospitalization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hochberg endpoint (combination of NT-proBNP and PGA)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuretic response (weight loss up to 72 hours and urine volume up to 24 hours)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcome - Need for mechanical ventilation (invasive and non-invasive</measure>
    <time_frame>7 days</time_frame>
    <description>Number of participants with post-enrollment respiratory failure with a need for mechanical ventilation as assessed by CTCAE v4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>High SpO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low SpO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High SpO2</intervention_name>
    <description>SpO2 range ≥96%</description>
    <arm_group_label>High SpO2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low SpO2</intervention_name>
    <description>SpO2 range 90-92%</description>
    <arm_group_label>Low SpO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;40 years of age presenting to the ED with AHF

          -  objective finding of HF (BNP &gt;400 pg/ml or Chest X-Ray with pulmonary congestion)

          -  plan to admit with primary diagnosis as HF

          -  must be able to be randomized within 16 hours of presenting to the ED

          -  provided written informed consent

        Exclusion Criteria:

          -  on home oxygen

          -  known prior hypercapnic failure (PaCO2 &gt;50 mmHg)

          -  asthma

          -  primary pulmonary hypertension,

          -  patients who require urgent positive pressure ventilation or intubation

          -  patients on &gt;10 L/min oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Ezekowitz, MBBCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nariman Sepehrvand, MD</last_name>
    <email>hilo@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital / Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Ezekowitz, MD</last_name>
      <email>hilo@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nariman Sepehrvand, MD</last_name>
      <email>hilo@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Ezekowitz, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

